A Study of DXC014 in Patients With Advanced Solid Tumors.

This is a phase I, open-label, first-in-human clinical study designed to evaluate the safety, tolerability, MTD, DLT, RP2D, the PK characteristics, preliminary anti-tumor activity, the immunogenicity of DXC014 in patients with Advanced Solid Tumors.

Trial Details

NCT ID
NCT07177937
Phase
PHASE1
Sponsor
Hangzhou DAC Biotechnology Co., Ltd.
Status
RECRUITING
Cancer Type
Melanoma
Interventions
  • DXC014
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723
  • Changsha, Hunan, China|28.19874,112.97087
  • Hangzhou, Zhejiang, China|30.29365,120.16142

Key Eligibility Criteria

  • Voluntarily sign the informed consent form and comply with the protocol requirements.
  • Male or female.
  • For other solid tumor patients: Age ≥18 years and ≤75 years；For prostate cancer patients: Age ≥18 years.
  • 4 .Life expectancy ≥ 3 months. 5. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →